Dysfunctional presynaptic M2 receptors in the presence of chronically high acetylcholine levels: Data from the PRiMA knockout mouse

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Mohr, Franziska ^a   Krejci, Eric ^b   Zimmermann, Martina ^a,c   Klein, Jochen ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINE RELEASE INHIBITOR; ACETYLCHOLINESTERASE; CHOLINE; MUSCARINIC M2 RECEPTOR; NEOSTIGMINE; OXOTREMORINE; SCOPOLAMINE; PRESYNAPTIC RECEPTOR;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; COGNITION; CONTROLLED STUDY; CORPUS STRIATUM; COUPLING FACTOR; DATA ANALYSIS; DEMENTIA; DOWN REGULATION; ENZYME ACTIVITY; EXTRACELLULAR SPACE; FEMALE; HIPPOCAMPUS; IN VIVO STUDY; INFANT; KNOCKOUT MOUSE; LEARNING; LONG TERM CARE; MEMORY CONSOLIDATION; MICRODIALYSIS; MOUSE; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PERINATAL PERIOD; POSTSYNAPTIC INHIBITION; PRESYNAPTIC NERVE; PROTEIN DEPLETION; PROTEIN FUNCTION; STRIATE CORTEX; ANIMAL; BIOSYNTHESIS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY;

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ANIMALS; COGNITION; CORPUS STRIATUM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HIPPOCAMPUS; HUMANS; MICE; MICE, KNOCKOUT; RECEPTOR, MUSCARINIC M2; RECEPTORS, PRESYNAPTIC;

EID: 84949651026     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141136     Document Type: Article

References (27)

1. Zhang W, Basile AS, Gomeza J, Volpicelli LA, Levey AI, Wess J. Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. J Neurosci. 2002; 22: 1709-1717. PMID: 11880500
2. Kruse AC, Kobilka BK, Gautam D, Sexton PM, Christopoulos A, Wess J. Muscarinic acetylcholine receptors: novel opportunities for drug development. Nature Rev Drug Discov. 2014; 13: 549-560.
3. Liu JK, Kato T. Effect of physostigmine on relative acetylcholine output induced by systemic treatment with scopolamine in in vivo microdislaysis of rat frontal cortex. Neurochem Int. 1994; 24: 589-596. PMID: 7981642
4. Köppen A, Klein J, Erb C, Löffelholz K. Acetylcholine release and choline availability in rat hippocampus: effects of exogenous choline and nicotinamide. J Pharmacol Exp Ther. 1997; 282: 1139-1145. PMID: 9316819
5. Quirion R, Wilson A, Rowe W, Aubert I, Richard J, Doods H, et al. Facilitation of acetylcholine release and cognitive performance by a M2-muscarinic receptor antagonist in aged memory-impaired rats. J Neurosci. 1995; 15: 1455-1462. PMID: 7869110
6. Lachowicz JE, Duffy RA, Ruperto V, Kozlowski J, Zhou G, Clader J, et al. Facilitation of acetylcholine release and improvement in cognition by a selective M2 muscarinic antagonist, SCH 72788. Life Sci. 2001; 66: 2585-2592.
7. Bernard V, Brana C, Liste I, Lockridge O, Bloch B. Dramatic depletion of cell surface M2 muscarinic receptor due to limited delivery from intracytoplasmic stores in neurons of acetylcholinesterase-deficient mice. Mol Cell Neurosci. 2003; 23: 121-133. PMID: 12799142
8. Volpicelli-Daley LA, Hrabovska A, Duysen EG, Ferguson SM, Blakely RD, Lockridge O, et al. Altered striatal function and muscarinic cholinergic receptors in acetylcholinesterase knockout mice. Mol Pharmacol. 2003; 64: 1309-1316. PMID: 14645660
9. Hartmann J, Kiewert C, Duysen EG, Lockridge O, Greig NH, Klein J. Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity. J Neurochem. 2007; 100: 1421-1429. PMID: 17212694
10. Xie W, Stribley JA, Chatonnet A, Wilder PJ, Rizzino A, McComb RD, et al. Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase. J Pharmacol Exp Ther. 2000; 293: 896-902. PMID: 10869390
11. Dobbertin A, Hrabovska A, Dembele K, Camp S, Taylor P, Krejci E, et al. Targeting of acetylcholinesterase in neurons in vivo: a dual processing function for the proline-rich membrane anchor subunit and the attachment domain on the catalytic subunit. J Neurosci. 2009; 29: 4519-4530. doi: 10.1523/JNEUROSCI.3863-08.2009 PMID: 19357277
12. Farar V, Mohr F, Legrand M, d'Incamps BL, Cendelin J, Leroy J, et al. Near-complete adaptation of the PRiMA knockout to the lack of central acetylcholinesterase. J Neurochem. 2012; 122: 1065-1080. doi: 10.1111/j.1471-4159.2012.07856.x PMID: 22747514
13. Farar V. Hrabovska A, Krejci E, Myslivecek J. Developmental adaptation of central nervous system to extremely high acetylcholine levels. PLoS ONE 8(7): e68265. doi: 10.1371/journal.pone.0068265 PMID: 23861875
14. Bernard V, Decossas M, Liste I, Bloch B. Intraneuronal trafficking of G-protein-coupled receptors in vivo. Trends Neurosci. 2006; 29: 140-147. PMID: 16443287
15. Nathanson NM. Synthesis, trafficking, and localisation of muscarinic acetylcholine receptors. Pharmacol Ther. 2008; 119: 33-43. doi: 10.1016/j.pharmthera.2008.04.006 PMID: 18558434
16. Mohr F, Zimmermann M, Klein J. Mice heterozygous for AChE are more sensitive to AChE inhibitors but do not respond to BuChE inhibition. Neuropharmacology 2013; 67: 37-45. doi: 10.1016/j. neuropharm.2012.11.001 PMID: 23147415
17. Li G, Klein J, Zimmermann M. Pathophysiological amyloid concentrations induce sustained upregulation of readthrough AChE mediating anti-apoptotic effects. Neuroscience 2013; 240: 349-360. doi: 10. 1016/j.neuroscience.2013.02.040 PMID: 23485809
18. Crawley JN. What' s wrong with my mouse? Behavioural phenotyping of transgenic and knockout mice. Wiley-Blackwell, Oxford, 2007.
19. Pepeu G, Giovannini MG. Cholinesterase inhibitors and beyond. Curr Alzheimer Res. 200); 6: 86-96.
20. Francis PT, Ramirez MJ, Lai MK. Neurochemical basis for symptomatic treatment of Alzheimer's disease. Neuropharmacology 2010; 59: 221-229. doi: 10.1016/j.neuropharm.2010.02.010 PMID: 20156462
21. Michal P, El-Fakahany EE, Dolezal V. Muscarinic M2 receptors directly activate Gq/11 and Gs G-proteins. J Pharmacol Exp Ther. 2007; 320: 607-614. PMID: 17065363
22. Moor E, Schirm E, Jacso J, Westerink BH. Effects of neostigmine and atropine on basal and handlinginduced acetylcholine output from ventral hippocampus. Neuroscience 1998; 82: 819-825. PMID: 9483538
23. Day JC, Kornecook TJ, Quirion R. Application of in vivo microdialysis to the study of cholinergic systems. Methods 2001; 23: 21-39. PMID: 11162147
24. Ringdahl B, Jenden DJ. Pharmacological properties of oxotremorine and its analogs. Life Sci. 1983; 32: 2401-2413. PMID: 6343743
25. Minic J, Molgó J, Karlsson E, Krejci E. Regulation of acetylcholine release by muscarinic receptors at the mouse neuromuscular junction depends on the activity of acetylcholinesterase. Eur J Neurosci. 2002; 15: 439-448. PMID: 11876771
26. Bohnen N, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Koeppe RA, et al. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005; 76: 315-319. PMID: 15716518
27. Hrabovska A, Krejci E. Reassessment of the role of the central cholinergic system. J Mol Neurosci. 2014; 53: 352-358. doi: 10.1007/s12031-013-0164-8 PMID: 24214089